{"nctId":"NCT02288247","briefTitle":"A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide Alone","startDateStruct":{"date":"2014-12-01","type":"ACTUAL"},"conditions":["Metastatic Castration Resistant Prostate Cancer"],"count":688,"armGroups":[{"label":"Enzalutamide","type":"EXPERIMENTAL","interventionNames":["Drug: Enzalutamide","Drug: Docetaxel","Drug: Prednisolone"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Docetaxel","Drug: Prednisolone","Drug: Placebo"]}],"interventions":[{"name":"Enzalutamide","otherNames":["Xtandi","ASP9785"]},{"name":"Docetaxel","otherNames":[]},{"name":"Prednisolone","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features;\n* Ongoing androgen deprivation therapy (ADT) with a luteinizing hormone-releasing hormone (LHRH) agonist or antagonist at a stable dose and schedule within 4 weeks of initiation of investigational medicinal product (IMP), or bilateral orchiectomy (i.e., surgical or medical castration);\n* Metastatic disease documented by at least 2 bone lesions on bone scan, or soft tissue disease documented by computed tomography (CT)/magnetic resonance imaging (MRI);\n* Progressive disease at study entry defined as the following occurring in the setting of castrate levels of testosterone: Prostate specific antigen (PSA) progression defined by a minimum of three rising PSA levels with an interval of ≥ 1 week between each determination.\n* Asymptomatic or minimally symptomatic prostate cancer (Brief Pain Inventory - Short Form (BPI-SF) question 3 score of \\< 4);\n* Eastern Cooperative Oncology Group (ECOG) performance score of 0-1;\n* Estimated life expectancy of ≥ 12 months;\n* Be suitable and willing to receive chemotherapy as part of the trial;\n* Able to swallow the IMP and comply with study requirements;\n* Subject agreed not to participate in another interventional study while on treatment.\n\nExclusion Criteria:\n\n* Prior treatment with the following agents for the treatment of prostate cancer: Aminoglutethimide; Ketoconazole; Abiraterone; Enzalutamide or participation in a clinical trial of enzalutamide; 223Ra, 89Sr, 153Sm, 186Re/188Re; Immunomodulatory therapies; Cytotoxic chemotherapy; Participation in a clinical trial of an investigational agent that inhibits the AR or androgen synthesis unless the treatment was placebo;\n* Current or prior treatment within 4 weeks prior to initiation of investigational medicinal product (IMP) with the following agents for the treatment of prostate cancer: Antiandrogens; 5-α reductase inhibitors; Estrogens; Anabolic steroids; Drugs with antiandrogenic properties; Progestational agents;\n* Subject had received investigational therapy within 28 days or 5 half-lives whichever was longer, prior to initiation of IMP;\n* Use of opiate analgesia for pain from prostate cancer within 4 weeks prior to initiation of IMP;\n* Radiation therapy to bone lesions or prostatic bed within 4 weeks prior to initiation of IMP;\n* Major surgery within 4 weeks prior to initiation of IMP;\n* History of seizure or any condition that may predispose to seizures at any time in the past. History of loss of consciousness or transient ischemic attack within 12 months prior to Screening;\n* Known or suspected brain metastasis or active leptomeningeal disease;\n* History of another malignancy within the previous 5 years other than non-melanoma skin cancer;\n* Clinically significant cardiovascular disease;\n* Gastrointestinal disorders affecting absorption;\n* Medical contraindications to the use of prednisolone or docetaxel;\n* Allergies to any of the active ingredients or excipients in the study drugs","healthyVolunteers":false,"sex":"MALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Progression Free Survival (PFS)","description":"PFS: time from randomization (Period 2 Week 1) to earliest progression event. Progression is defined as radiographic progression, unequivocal clinical progression, or death on study. Radiographic progression is defined for bone disease by appearance of ≥ 2 new lesions on whole-body radionuclide bone scan per Prostate Cancer Clinical Trials Working Group 2 (PCWG2) criteria (i.e., unconfirmed progressive disease) that needs to be confirmed in the next assessment (i.e., progressive disease in the next assessment) or for soft tissue disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Unequivocal clinical progression is defined as new onset cancer pain requiring chronic administration of opiate analgesia or deterioration from prostate cancer of Eastern Cooperative Oncology Group (ECOG) performance status score to ≥ 3, or initiation of subsequent lines of cytotoxic chemotherapy or radiation therapy or surgical intervention due to complications of tumor progression.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.53","spread":null},{"groupId":"OG001","value":"8.28","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Prostate-specific Antigen (PSA) Progression","description":"Time to PSA progression, defined as the time from randomization (Period 2 Week 1) to the date of the first PSA value in Period 2 demonstrating progression (Period 2). The PSA progression date is defined as the date that a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the nadir recorded in Period 2 is documented, which must be confirmed by a second consecutive value obtained at least 3 weeks later.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.44","spread":null},{"groupId":"OG001","value":"6.24","spread":null}]}]}]},{"type":"SECONDARY","title":"Prostate-specific Antigen (PSA) Response","description":"PSA response, defined as a decrease in percentage change from randomization (Period 2 Week 1) of 50% or more. PSA response was derived at Week 13 and at any time after randomization in Period 2. PSA response at any time is defined as a decrease in percentage change from randomization (Period 2 Week 1) at any time after randomization of 50% or more. Percentage of participants with PSA response was reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.9","spread":null},{"groupId":"OG001","value":"25.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55.9","spread":null},{"groupId":"OG001","value":"37.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Objective Response Rate (ORR)","description":"ORR, defined as the best overall radiographic response after randomization (Period 2 Week 1) as per Investigator assessments of response for soft tissue disease per RECIST 1.1, in participants who had a measurable tumor. ORR was reported as the percentage of participants with complete response (CR) or partial response (PR). CR was defined as disappearance of all target and nontarget lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \\< 10 mm from baseline measurement. PR was defined as at least a 30% decrease in the sum of diameters (longest for nonnodal lesions, short axis for nodal lesions) of target lesions taking as reference to the baseline sum of diameters.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.6","spread":null},{"groupId":"OG001","value":"25.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Pain Progression","description":"The time to an increase of \\>=30% from randomization (Period 2 Week 1) in average BPI-SF item scores (items 3, 4, 5, 6) at two consecutive evaluations \\>=3 weeks apart without decrease in analgesic score according to the World health Organization (WHO). Only participants with an average pain intensity item score \\>=4 were considered. The BPI-SF was an instrument to document pain-related functional impairment and contains 7 questions which included pain intensity \\[(items 3, 4, 5 and 6): worst pain, least pain, average pain and current pain, with scales from 0 (no pain) to 10 (pain as bad as you can imagine)\\] and pain interference \\](items 9A to 9G): general activity, mood, walking ability, normal work, relations with other people, sleep and enjoyment of life, with scales from 0 (does not interfere) to 10 (completely interferes)\\]. The BPI-SF total score for pain intensity was calculated as the mean of the 4 scores for the 4 items of pain intensity.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Time to Opiate Use for Cancer-related Pain","description":"Time to opiate use for cancer-related pain, defined as the time from randomization (Period 2 Week 1) to initiation of chronic administration of opiate analgesia \\[parenteral opiate use for ≥7 days or use of WHO Analgesic Ladder Level 3 oral opiates for ≥3 weeks\\].","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Time to First Skeletal-related Event (SRE)","description":"Time to first SRE, defined as the time from randomization (Period 2 Week 1) to radiation therapy or surgery to bone, pathologic bone fracture, spinal cord compression, or change of antineoplastic therapy to treat bone pain.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.98","spread":null},{"groupId":"OG001","value":"17.35","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Functional Assessment of Cancer Therapy - Prostate (FACT-P)","description":"FACT-P quality of life questionnaire is a multi-dimensional, self-reported quality of life instrument specifically designed for use with prostate cancer participants. It consists of 27 core items which assess participant function in four domains rated on 0 to 4 Likert-type scale: physical well-being (PWB) (7 items; 0 \\[worst\\] to 4 \\[better\\], score range 0-28), social/family well-being (SWB) (7 items; 0 \\[worst\\] to 4 \\[better\\], score range 0-28), emotional well-being (EWB) (6 items; 0 \\[worst\\] to 4 \\[better\\], score range 0-24), and functional well-being (FWB) (7 items; 0 \\[worst\\] to 4 \\[better\\], score range 0-28), which is further supplemented by 12 site-specific items to assess for prostate-related symptoms (Prostate Cancer Subscale \\[PCS\\] 12 items rated on Likert-type scale 0 \\[worst\\] to 4 \\[better\\], score range 0-48). The total domain scores and PCS subscale score are then combined to a global quality of life score ranging between 0 to 156; higher scores representing better quality of life.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"},{"groupId":"OG001","value":"0.00","spread":"0.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"},{"groupId":"OG001","value":"0.00","spread":"0.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.15","spread":"4.15"},{"groupId":"OG001","value":"1.36","spread":"3.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.69","spread":"3.85"},{"groupId":"OG001","value":"1.03","spread":"3.58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.91","spread":"3.85"},{"groupId":"OG001","value":"1.43","spread":"3.73"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.22","spread":"3.62"},{"groupId":"OG001","value":"0.73","spread":"4.24"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.59","spread":"4.52"},{"groupId":"OG001","value":"2.00","spread":"3.58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.69","spread":"3.13"},{"groupId":"OG001","value":"-1.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":"4.06"},{"groupId":"OG001","value":"-5.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.90","spread":"4.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.93","spread":"3.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.00","spread":"2.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.00","spread":"0.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0000","spread":"0.0000"},{"groupId":"OG001","value":"0.0000","spread":"0.0000"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0000","spread":"0.0000"},{"groupId":"OG001","value":"0.0000","spread":"0.0000"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.8144","spread":"5.0586"},{"groupId":"OG001","value":"-0.3121","spread":"4.7437"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.4472","spread":"5.2508"},{"groupId":"OG001","value":"-0.8229","spread":"5.2563"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5697","spread":"6.3251"},{"groupId":"OG001","value":"-0.1459","spread":"3.2857"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1579","spread":"6.7284"},{"groupId":"OG001","value":"-1.3818","spread":"4.5238"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0000","spread":"4.7651"},{"groupId":"OG001","value":"-2.3333","spread":"2.8048"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.8182","spread":"3.5726"},{"groupId":"OG001","value":"-2.0000","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2000","spread":"4.8166"},{"groupId":"OG001","value":"0.0000","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5000","spread":"1.7321"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.3333","spread":"3.2146"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5000","spread":"0.7071"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5000","spread":"2.1213"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.0000","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0000","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0000","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0000","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0000","spread":"0.0000"},{"groupId":"OG001","value":"0.0000","spread":"0.0000"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0000","spread":"0.0000"},{"groupId":"OG001","value":"0.0000","spread":"0.0000"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7836","spread":"17.7356"},{"groupId":"OG001","value":"1.7986","spread":"16.3294"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.9204","spread":"18.2107"},{"groupId":"OG001","value":"1.0762","spread":"17.0168"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5351","spread":"20.3721"},{"groupId":"OG001","value":"0.1649","spread":"15.8335"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.4880","spread":"24.6865"},{"groupId":"OG001","value":"-4.6202","spread":"17.9530"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2957","spread":"17.6915"},{"groupId":"OG001","value":"6.0939","spread":"8.8208"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3917","spread":"18.3346"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7636","spread":"11.7476"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.2864","spread":"9.8128"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.7333","spread":"17.6299"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.0000","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.0000","spread":"4.2426"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.0000","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0000","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.0000","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.0000","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0000","spread":"0.0000"},{"groupId":"OG001","value":"0.0000","spread":"0.0000"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0000","spread":"0.0000"},{"groupId":"OG001","value":"0.0000","spread":"0.0000"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.3322","spread":"6.0823"},{"groupId":"OG001","value":"-0.6347","spread":"4.4643"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.1317","spread":"6.5208"},{"groupId":"OG001","value":"-0.4590","spread":"4.2887"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.1786","spread":"5.5611"},{"groupId":"OG001","value":"-0.9556","spread":"4.3691"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.5316","spread":"8.0882"},{"groupId":"OG001","value":"-1.3913","spread":"6.1625"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.3889","spread":"6.9886"},{"groupId":"OG001","value":"1.3333","spread":"3.8297"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3636","spread":"8.0408"},{"groupId":"OG001","value":"3.0000","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0000","spread":"10.3682"},{"groupId":"OG001","value":"3.0000","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7500","spread":"10.4363"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6667","spread":"13.6504"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.0000","spread":"1.4142"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.5000","spread":"0.7071"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.0000","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0000","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.0000","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.0000","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0000","spread":"0.0000"},{"groupId":"OG001","value":"0.0000","spread":"0.0000"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0000","spread":"0.0000"},{"groupId":"OG001","value":"0.0000","spread":"0.0000"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1842","spread":"6.1843"},{"groupId":"OG001","value":"1.6011","spread":"6.0731"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4775","spread":"6.2665"},{"groupId":"OG001","value":"1.8632","spread":"6.3433"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1433","spread":"7.3006"},{"groupId":"OG001","value":"0.6988","spread":"7.1353"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.8465","spread":"8.6083"},{"groupId":"OG001","value":"-0.7223","spread":"7.8442"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3690","spread":"6.0031"},{"groupId":"OG001","value":"4.2606","spread":"3.1148"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9174","spread":"7.8001"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1636","spread":"5.6123"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8864","spread":"3.3380"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.6667","spread":"5.8595"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0000","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.0000","spread":"4.2426"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.0000","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0000","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.0000","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.0000","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0000","spread":"0.0000"},{"groupId":"OG001","value":"0.0000","spread":"0.0000"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0000","spread":"0.0000"},{"groupId":"OG001","value":"0.0000","spread":"0.0000"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1581","spread":"4.1893"},{"groupId":"OG001","value":"-0.2953","spread":"5.0738"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3634","spread":"5.6959"},{"groupId":"OG001","value":"-0.0462","spread":"3.7933"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8798","spread":"4.6897"},{"groupId":"OG001","value":"-0.3963","spread":"3.3279"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.0719","spread":"6.2561"},{"groupId":"OG001","value":"-0.7536","spread":"4.3164"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8167","spread":"3.3323"},{"groupId":"OG001","value":"0.8333","spread":"5.7067"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8182","spread":"2.7863"},{"groupId":"OG001","value":"-24.0000","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.6000","spread":"3.7815"},{"groupId":"OG001","value":"-24.0000","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.7500","spread":"5.8523"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.0000","spread":"4.3589"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5000","spread":"0.7071"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0000","spread":"1.4142"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.0000","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.0000","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.0000","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.0000","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in EuroQOL 5-dimension 5-level Questionnaire [EQ-5D-5L] Visual Analog Scale (VAS)","description":"The EQ-5D-5L VAS records the participant's self-rated health on a vertical visual analogue scale, where the endpoints are labelled from 0 (worst health imaginable) to 100 (best health imaginable).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.0"},{"groupId":"OG001","value":"0.0","spread":"0.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.0"},{"groupId":"OG001","value":"0.0","spread":"0.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"19.7"},{"groupId":"OG001","value":"-0.8","spread":"17.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.0","spread":"18.6"},{"groupId":"OG001","value":"-0.2","spread":"17.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","spread":"21.7"},{"groupId":"OG001","value":"0.4","spread":"15.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.5","spread":"25.7"},{"groupId":"OG001","value":"-8.3","spread":"23.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"22.6"},{"groupId":"OG001","value":"2.5","spread":"25.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.5","spread":"30.8"},{"groupId":"OG001","value":"-20.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.2","spread":"20.7"},{"groupId":"OG001","value":"-10.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.8","spread":"27.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.7","spread":"23.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.0","spread":"4.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"13.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":238,"n":687},"commonTop":["Fatigue","Asthenia","Back pain","Diarrhoea","Nausea"]}}}